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Oxidative stress and cardiovascular disease are risk factor of
patients with chronic kidney disease (CKD) on maintenance
hemodialysis. We used the fluorescence of low-density
lipoprotein as an index of its proinflammatory potential to
examine any role that high-density lipoprotein (HDL) might
have in promoting this effect. The total body fat of the
patients was measured by means of near-infrared
interactance and their quality of life by means of SF36
questionnaires. In 189 randomly selected patients, followed
for 30 months, HDL was found to be significantly anti-
inflammatory but with a large standard deviation. Fully 17%
of the patients had a decidedly proinflammatory index along
with inferior SF36 scores. The patients were divided into 10%
increments of total body fat percentages up to 40%. HDL was
found to be progressively proinflammatory the higher the
body fat content. Patients with a higher HDL
proinflammatory index had a higher 30-month adjusted
hazard ratio for death than those whose HDL were seen to be
anti-inflammatory. Our findings suggest an important role of
inflammatory HDL in patients with CKD leading to poor
outcome.
Kidney International (2007) 72, 1149–1156; doi:10.1038/sj.ki.5002491;
published online 29 August 2007
KEYWORDS: HDL; LDL; chronic kidney disease; dialysis; inflammation;
cardiovascular disease; hemodialysis
Individuals with chronic kidney disease (CKD) have a very
high mortality rate and a high burden of cardiovascular
disease.1 At least one of every five CKD patients requiring
maintenance dialysis treatment, currently B400 000 indivi-
duals in the United States, dies every year.2 This results in a 5-
year survival rate of o35%, worse than the survival rate of
many malignant diseases.2 Half of all deaths are attributed to
cardiovascular disease.2 However, such traditional risk factors
as hypercholesterolemia, hypertension, and obesity do not
appear to be related to cardiovascular death risk in dialysis
patients. Indeed, a low, rather than a high, serum cholesterol
or low-density lipoprotein (LDL) level is associated with
poor survival in these individuals.3 A recent randomized trial,
Die Deutsche Diabetes-Dialyse (4D) Study, did not show a
significant reduction in mortality with cholesterol lowering
by atorvastatin in diabetic dialysis patients.4
Most observational studies indicate that malnutrition,
inflammation, and/or oxidative stress, together known as the
‘malnutrition–inflammation complex (or cachexia) syn-
drome’ (MICS) may be a much stronger predictor of death
risk in dialysis patients than traditional cardiovascular risk
factors.5,6 Lipoprotein oxidation appears to play a central role
in atherogenesis.7–10 The oxidation hypothesis of atherogen-
esis pertains to specific proinflammatory oxidized phospho-
lipids.7,11–13 The oxidized phospholipids are largely generated
by potent oxidants produced by the lipoxygenase and
myeloperoxidase pathways.7,14 Recent evidence suggests that
the function of high-density lipoprotein (HDL) can be
dramatically altered by these oxidants and the oxidized lipids
formed by their action.7,10,15–17
A measure of HDL inflammatory/anti-inflammatory
properties has been shown to distinguish patients with
atherosclerotic cardiovascular disease (or metabolic equiva-
lents such as long-standing diabetes) from healthy control
subjects better than HDL-cholesterol levels.18 To our knowl-
edge, these properties of HDL have neither yet been
measured in individuals with CKD undergoing maintenance
hemodialysis (MHD) treatment, nor has its association with
body composition or markers of MICS or its association with
clinical outcomes including quality of life and mortality been
examined in the CKD population. We report here that the
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inflammatory/anti-inflammatory properties of HDL identi-
fied a cohort of MHD patients who were at exceptionally
high risk for death in the 30 months following the
measurement.
RESULTS
HDL-inflammatory index (HII) was assessed in all 189
randomly selected serum samples (Figure 1) and averaged
0.50170.574 (mean7s.d., median: 0.289). In patients with a
previous history of cardiovascular disease (n¼ 122), the
averaged HII (0.56370.458) was 0.178 higher than those
without cardiovascular disease history (P¼ 0.02). Thirty-
three patients (17%) had an HII41.0. Table 1 shows the
relevant demographic, clinical, and laboratory measures in
the two categories of MHD patients (HIIo1.0 versusX1.0).
The MHD patients with HIIX1 had significantly higher
comorbidities according to the Charlson score and worse self-
reported quality of life, but higher body mass index, larger
total body fat, and thicker upper arm skinfolds. Among
laboratory measures, serum albumin levels, one of the
strongest predictors of survival in dialysis patients,19 were
not significantly different between the two HII groups.
Similarly, serum lipoprotein levels, including HDL-cholester-
ol, were similar in the two groups, suggesting that HII is
independent of the serum HDL-cholesterol level. Among
inflammatory markers, serum C-reactive protein (CRP) was
slightly higher in the HIIX1 group, but interleukin (IL)-6
and tumor necrosis factor-a were similar in the two groups of
patients. Predialysis serum creatinine,20 an indicator of
muscle mass and probably meat intake, was lower in subjects
with HIIX1.
Table 2 shows the association between SF36 scores and
HII. All eight scales and the two main dimensions (physical
and mental health) of the SF36 had inverse correlations with
HII, that is, better self-reported quality of life with lower HII
values, although the correlation coefficients were small. The
reported quality of life was consistently worse among those
who had HIIX1; the difference between the two HII groups
was more prominent for the scales Physical Function and
Role Emotional.
To further examine the nature of the association between
the measured body fat and HII, the near infrared (NIR)
measured total body fat categories were divided into five a
priori selected categories ofo10,X40 and three 10% groups
in-between. As shown in Table 3, both the absolute HII level
and the proportion of patients with an HIIX1 were
progressively greater in MHD patients with a larger percent
of body fat. To examine if the association between the total
body fat and HII was due to other confounding demographic
or clinical variables, logistic regression analyses were
conducted. Table 4 and Figure 2 show the odds ratios of
HIIX1 in each of the body fat categories. Comparing the
10–19.9% body fat group, the odds of an HIIX1 was 4–10
times higher in MHD patients with larger total body fat
percent, and these associations were independent of other
covariates.
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Figure 1 | Distribution of the measured ‘HDL-inflammatory index’
(HII) in 189 MHD patients.
Table 1 | Relevant demographic, clinical, and laboratory
values according to the HII cutoff level of 1.0 in 189 MHD
patients at baseline
HIIo1 HIIX1 P-values
Number of MHD patients 156 (83%) 33 (17%)
Gender (% women) 42 61 0.05
Diabetes mellitus (%) 50 67 0.08
Race (% Blacks) 28 23 0.3
Ethnicity (% Hispanics) 51 58 0.3
Age (years) 5471 5672 0.5
Dialysis vintage (months) 38734 32723 0.4
Charlson comorbidity score 1.971.4 2.771.5 0.003
SF36 quality of life score 57726 47717 0.02
Body composition
NIR measured body fat (%) 24.4710.6 31.679.2 o0.001
Body mass index (kg/m2) 25.275.5 28.177.9 0.02
Triceps skinfold (mm) 15.9710.0 20.5710.5 0.02
Biceps skinfold (mm) 10.077.9 13.178.6 0.05
Dialysis dose (Kt/V) 1.6070.27 1.7270.28 0.02
Protein intake (g/kg/day) 1.0770.24 1.0970.23 0.6
Serum concentrations
HII 0.29770.328 1.45570.524 o0.001
Albumin (g/dl) 3.9270.39 3.8370.35 0.17
Ferritin (ng/ml) 6347389 7777697 0.05
Iron saturation (%) 34712 40715 0.01
Creatinine (mg/dl) 11.373.3 8.972.8 o0.001
Total cholesterol (mg/dl) 147739 146728 0.9
LDL (mg/dl) 81731 77720 0.5
HDL (mg/dl) 38714 36716 0.5
Triglyceride (mg/dl) 1297113 131755 0.9
Total homocysteine (mmol/l) 27712 25712 0.4
CRP (mg/l) 5.276.7 6.776.2 0.03*
IL-6 (pg/ml) 18761 13727 0.7*
TNF-a (pg/ml) 9.3711.9 7.174.7 0.3*
CRP, C-reactive protein; HDL, high-density lipoprotein; HII, HDL-inflammatory index;
IL-6, interleukin-6; LDL, low-density lipoprotein; MHD, maintenance hemodialysis;
NIR, near infrared; SF36, short form quality of life score with 36 questions; TNF,
tumor necrosis factor.
P-value pertains to t-test.
*P-values for CRP, IL-6, and TNF-a are based on the logarithmic values of these
measures.
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During the 30 months of prospective longitudinal
observation (1 July 2002 through 31 December 2004), 46
patients died, 22 underwent renal transplantation, and 4 were
lost to follow-up. The remaining 117 subjects were confirmed
alive as of early January 2005. Among patients with HIIX1,
35 subjects (22%) died versus 11 subjects (33%) in those with
HIIo1. To examine whether HIIX1 at the baseline of the
cohort was associated with a higher death rate, Kaplan–Meier
plots were constructed. Figure 3 shows that by the end of the
30 months of observation, the MHD patients with an HIIX1
had worse survival, although this difference was not
statistically significant. The survival difference between the
two HII groups was more prominent and statically significant
after adjusting for case-mix covariates (P¼ 0.03; Figure 3,
lower panel). Table 5 compares the hazard ratios of HIIX1
with serum albumino3.8 g/dl, CRPX10 mg/l, and IL-
6X10 pg/ml. In the fully adjusted model, HIIX1 was
associated with 2.47-fold higher risk of death compared to
HIIo1 (95% confidence interval: 1.14–5.34, P¼ 0.02).
Among other nutritional and inflammatory measures,
hypoalbuminemia was the only statistically significant
predictor of death (Table 5). Inclusion of serum creatinine,
Table 2 | SF36 quality of life score and its association with HII
Correlation with HII levels HIIo1 (n=156) HIIX1 (n=33) P-values
SF36 total score 0.28 (Po0.001) 57726 47717 0.02
SF36 dimensions (2)
SF-36 mental health 0.26 (Po0.001) 59725 50716 0.03
SF-36 physical health 0.24 (Po0.001) 51727 41718 0.03
SF36 scales (8)
Body pain 0.14 (P=0.06) 59729 55726 0.3
General health 0.18 (P=0.02) 44722 40721 0.16
Mental health 0.11 (P=0.16) 67721 63718 0.17
Physical function 0.28 (Po0.001) 54733 38728 0.008
Role emotional 0.20 (P=0.01) 64784 38744 0.04
Role physical 0.21 (P=0.006) 49784 24737 0.06
Functionality 0.16 (P=0.04) 69731 67723 0.4
Vitality 0.14 (P=0.07) 49724 42721 0.06
HII, high-density lipoprotein inflammatory index; SF36, short form quality of life score with 36 questions.
The first column shows the correlation coefficients between the two main dimensions and eight scales of the health-related quality of life and HII in 189 MHD patients. The
following columns compare SF36 scores in patients with HII o1 versus X1 (P-value is based on the t-test).
Table 3 | The association between total body fat, measured by the NIR interactance, and the serum HII concentration
NIR body fat (%) Number of MHD patients in each category HII (mean7s.d.) Number of MHD patients with HIIX1
o10 14 (7%) 0.09970.234 0 (0%)
10–19.9 52 (28%) 0.40570.515 3 (6%)
20–29.9 51 (27%) 0.53170.485 10 (20%)
30–39.9 51 (27%) 0.58470.617 13 (25%)
X40 21 (11%) 0.73870.816 7 (35%)
All patients 189 (100%) 0.50170.574 33 (17%)
HII, high-density lipoprotein inflammatory index; MHD, maintenance hemodialysis; NIR, near infrared.
Body fat is categorized into five a priori categories based on increments of 10%.
Table 4 | Odds ratio of HIIX1 based on the body fat categories in the cohort in 189 MHD patients of the NIED Study
NIR body fat (%) Unadjusted Case-mix adjusteda Case-mix and MICS adjustedb
o10b 51.0 51.0 51.0
10–19.9 (reference group) 1.0 1.0 1.0
20–29.9 4.0 (1.1–15.4) 4.7 (1.1–19.5) 4.8 (1.2–20.0)
P=0.04 P=0.03 P=0.03
30–39.9 5.6 (1.5–21.0) 6.5 (1.3–31.8) 6.1 (1.2–30.2)
P=0.01 P=0.02 P=0.03
X40 8.8 (2.0–38.8) 10.6 (1.7–64.6) 9.7 (1.6–59.4)
P=0.004 P=0.01 P=0.02
CRP, C-reactive protein; HII, high-density lipoprotein inflammatory index; IL-6, interleukin-6; MHD, maintenance hemodialysis; MICS, malnutrition–inflammation–cachexia
syndrome; NIED, Nutritional and Inflammatory Evaluation in Dialysis Study; NIR, near infrared.
aCase-mix models are adjusted for age, gender, race and ethnicity, diabetes, Charlson comorbidity scale, and dialysis vintage. Case-mix and MICS-adjusted models are also
controlled for serum albumin, CRP, and IL-6.
bNone of the MHD patients with a total body fat o10% had HIIX1; hence, a mathematic OR cannot be calculated, because the logarithm of OR is minus infinity for this
group.
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a possible muscle mass indicator, in the fully adjusted Cox
model resulted in similar death hazard ratio estimates for
HIIX1 (data not shown).
DISCUSSION
Seventeen percent of 189 MHD patients at the start of a 30-
month period of observation had an HIIX1. HDL-
cholesterol and other lipoprotein levels in the patients with
HIIX1 were similar from those with HIIo1. All scales of
SF36 health-related quality of life were reported worse in
subjects with HIIX1. Body composition had a bearing on the
HII, in that HII was progressively higher across the larger
total body fat categories, and this association was indepen-
dent of demographic and clinical characteristics or the
severity of comorbid conditions. In this prospective study,
the MHD patients with HIIX1 had approximately a 2.5-fold
higher adjusted death risk independent of other mortality
predictors, including body fat or hypoalbuminemia. These
findings may have important clinical implications for the
management of inflammation and oxidative stress and
subsequent atherosclerotic cardiovascular disease in MHD
patients.
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Figure 2 | Odds ratio of HIIX1 in 189 MHD patients among the a
priori selected categories of total body fat percentage based on
fat percentage increments of 10%. Case-mix models are adjusted
for age, gender, race and ethnicity, diabetes, Charlson comorbidity
scale, and dialysis vintage. Case-mix and MICS-adjusted models are
also controlled for serum albumin, CRP, and IL-6.
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Figure 3 | Kaplan–Meier proportion of surviving MHD patients
after 30 months of observation using an HII cutoff level of 1 in
the cohort of 189 MHD patients of the NIED Study. Upper panel:
unadjusted survival. Lower panel: adjusted for case-mix variables,
including age, race and ethnicity (Blacks, Asians, and Hispanics),
diabetes mellitus, Charlson comorbidity score, dialysis vintage,
dialysis dose (Kt/V), and body fat percentage according to the NIR
measurements.
Table 5 | Hazard ratio of 30-month death according to the HII cutoff level of 1 in 189 MHD patients of the NIED Study
3-year hazard ratio of death in 189 MHD patients
Unadjusted Case-mixa Case-mix and MICS (full model)b
HIIX1 1.61 (0.82–3.18) 2.37 (1.10–5.12) 2.47 (1.14–5.34)
P=0.16 P=0.03 P=0.02
Albumino3.8 g/dl 3.41 (1.89–6.19) 2.49 (1.26–4.09) 2.39 (1.18–4.87)
Po0.001 P=0.01 P=0.02
CRPX10 mg/l 1.39 (0.67–2.87) 1.02 (0.48–1.23) 0.81 (0.37–1.77)
P=0.4 P=0.9 P=0.6
IL-6X10 pg/ml 1.76 (1.00–3.14) 1.52 (0.81–2.83) 1.30 (0.68–2.46)
P=0.05 P=0.19 P=0.4
CRP, C-reactive protein; HII, high-density lipoprotein inflammatory index; IL-6, interleukin-6; MHD, maintenance hemodialysis; MICS, malnutrition–inflammation–cachexia
syndrome; NIED, Nutritional and Inflammatory Evaluation in Dialysis Study.
aCase-mix model is adjusted for age, race and ethnicity (Blacks, Asians, and Hispanics), diabetes mellitus, Charlson comorbidity score, dialysis vintage, dialysis dose (Kt/V), and
body fat percentage according to the NIR measurements.
bCase-mix and MICS model (the full model) also includes serum albumin (o3.8 versus X3.8), CRP (X10 versus less), and IL-6 (X10 versus less).
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Inflammation and oxidative stress are likely contributors
to morbidity, lower health-related quality of life, and
mortality in MHD patients.21 Although in the general
population higher HDL is associated with better survival, a
recent study did not find any association between HDL and
survival in MHD patients.22 Qualitative abnormalities of
HDL function in MHD patients were reported in an in vitro
study by Morena et al.23 including the reduction of HDL
protective capacity against oxidative stress because of
impairment of LDL oxidation prevention and impairment
of reverse cholesterol transport by HDL in these patients.
Several studies have indicated an association between low
serum total cholesterol and poor survival of dialysis
patients.22,24,25 An observational study by Liu et al.26 showed
that MICS may be the cause of the inverse association
between cholesterol and mortality in these patients. In the 4D
Study,4 1255 diabetic dialysis patients were randomized to
receive either atorvastatin (20 mg/day) or placebo for 5 years.
The study was recently reported to be negative4 with a
nonsignificant 8% reduction of the primary composite end
points achieved by treatment with the cholesterol/LDL-
lowering agent. This was in distinct contrast to the recently
published CARDS trial (Collaborative Atorvastatin Diabetes
Study)27 in type II diabetic patients who had not yet
developed significant kidney disease. Hence, the association
between traditional risk factors and survival in CKD patients
is likely confounded by factors related to CKD and MHD.
Protein-energy malnutrition and inflammation, indepen-
dently or together as in MICS, are common occurrences in
CKD patients.5,28 MICS is associated with poor clinical
conditions and worse outcomes.29,30 The confounding effect
of MICS on associations between traditional risk factors such
as obesity and hypercholesterolemia and clinical outcome is
so strong that it even reverses these associations. Hence, a
low, rather than a high, body mass index or serum cholesterol
level is associated with mortality in MHD patients.24,31 This
phenomenon has been termed reverse epidemiology3 and is
also observed in individuals with chronic heart failure.32 In
our study in MHD patients, high HII values were associated
with a higher body fat percentage and body mass index,
indicating a ‘paradox within the paradox’.33 In this subset of
MHD patients with high HII, the positive association
between higher body fat mass and better survival in dialysis
patients was not observed, rather the reverse was true.34 The
increased HII appeared to reverse the benefit of higher body
fat mass seen in a general MHD population. It should be
noted that in the high HII group serum creatinine, a
surrogate of muscle mass linked to greater survival in dialysis
patients,35 was significantly lower, whereas diabetes and
female gender were more prevalent. However, the mortality
predictability of HIIX1 was independent of the said
covariates.
A potential limitation of this study is a selection bias
during enrollment. However, as the mortality in our cohort
was less than the base population, it might be argued that a
selection bias with such a direction generally would lead to a
bias toward the null, so without this bias, our positive results
may have been even stronger. In our cohort, CRP was not
associated with mortality, and the mortality predictability of
IL-6 lost statistical significance after multivariate adjustment.
However, serum albumin remained a strong predictor of
survival. Another potential limitation is that the HII
measurement methodology and criteria, including using the
cutoff point of 1.0, were originally developed and tested in
patient populations without CKD.18,36 However, we have
shown that using the same criteria HII has significant
associations with relevant clinical measures and outcomes in
MHD patients. Our and similar data18,36 indicate that the
composition of HDL may be different in patients with
increased HII. Future studies are to examine the HDL
composition in this regard. Finally, in this study we did not
include an a priori selected non-dialysis (control) group.
However, two previous studies18,36 included separate control
groups, in whom HII averaged 0.6618 and 0.68.36
The strengths of this study include the sample size, which
was moderately large, the comprehensive clinical and
laboratory evaluations, and the inclusion of many individuals
with diabetes mellitus. Unlike previous cohorts that have
been studied, ours has been extensively characterized for
markers of inflammation and nutritional status, including
direct total body fat measurements. The availability of these
measures allowed us to demonstrate that HII was able to
predict mortality risk independent of influences from other
known inflammatory markers or comorbid states in this
group of MHD patients. Another strength of this cohort is
that the subjects were selected randomly without having any
previous knowledge of their oxidative stress or inflammation
status. Finally, the very same blood specimens that were
utilized to measure markers of MICS and cytokines were also
used for the HII measurements.
In conclusion, we found that serum HII correlated with
several surrogates of body composition and poor quality of
life in MHD patients. Moreover, HIIX1 was independently
associated with increased death risk. Understanding the role
of HDL inflammatory properties in the CKD population may
lead to new diagnostic and therapeutic approaches for the 20
million individuals with CKD.
MATERIALS AND METHODS
Patient population
Subjects participating in the Nutritional and Inflammatory Evalua-
tion in Dialysis (NIED) Study originated from a pool of
approximately 1300 MHD outpatients in eight DaVita Inc., chronic
dialysis facilities in the South Bay Los Angeles area (see NIED Study
website at http://www.NIEDStudy.org for more details, as well as
previous publications14,37,38). Inclusion criteria were outpatients
who had been undergoing MHD for at least 8 weeks, were 18 years
or older and who signed a local Institutional Review Board-
approved consent form. Patients with an anticipated life expectancy
of less than 6 months (e.g., due to a metastatic malignancy or
advanced HIV disease) were excluded. From July through December
2002, blood samples were obtained from 189 MHD patients from
eight DaVita dialysis clinics had given informed written consent to
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participate in the NIED Study and whose sera were adequate for
measurement of HDL inflammatory/anti-inflammatory properties.
The medical chart of each MHD patient was thoroughly
reviewed by a collaborating physician, and data pertaining to
underlying kidney disease, cardiovascular history, and other
comorbid conditions were extracted. A modified version of the
Charlson comorbidity index, that is, without the age and kidney
disease components, was used to assess the severity of comorbid-
ity.39,40 The 189 MHD patients were followed for up to 30 months,
that is, until 31 December 2004.
SF36 health-related quality of life scores
The SF36, assessed before blood measurements, is a short form
health-related quality of life scoring system with 36 items, including
eight independent scales. It is a well-documented, self-administered
questionnaire and has been widely used and validated in MHD
patients.41,42 The eight scales of SF36 are summarized into two
dimensions: ‘physical health’ and ‘mental health’.
Anthropometric measures
Body weight assessment and anthropometric measurements were
performed while patients were undergoing a hemodialysis treatment
or within 5–20 min after termination of the treatment. Biceps
skinfold and triceps skinfold thicknesses were measured with a
conventional skinfold caliper using standard techniques as described
elsewhere.43,44
Near-infrared interactance
To measure the percentage of body fat and estimate fat-free body
mass, NIR interactance technology was utilized at the same time as
the anthropometric measurements.45,46 A commercial NIR inter-
actance sensor with a coefficient of variation of 0.5% for total body
fat measurement (portable Futrex 6100s, Gaithersburg, MD, USA,
http://www.futrex.com) was used. NIR measurements were per-
formed by placing a Futrex sensor on the non-access upper arm for
several seconds, after entering the required data (date of birth,
gender, weight, and height) from each patient. NIR measurements
of body fat have been shown to correlate significantly with other
nutritional measures in MHD patients.46
Laboratory tests
Predialysis blood samples and postdialysis serum urea nitrogen were
obtained on a mid-week day and coincided chronologically with the
drawing of quarterly blood tests in the DaVita facilities. The single-
pool Kt/V was used to represent the weekly dialysis dose. All routine
laboratory measurements were performed by DaVitas Laboratories
(Deland, FL, USA) using automated methods.
Serum high-sensitivity CRP was measured by a turbidometric
immunoassay in which a serum sample is mixed with latex beads
coated with anti-human CRP antibodies forming an insoluble
aggregate (mg/l, normal range: o3.0 mg/l; WPCI, Osaka, Ja-
pan).47,48 IL-6 and tumor necrosis factor-a were measured using
immunoassay kits based on a solid phase sandwich enzyme-linked
immunosorbent assay using recombinant human IL-6 and tumor
necrosis factor-a (pg/ml, normal range: o9.9 pg/ml (IL-6) and
o4.7 pg/ml (tumor necrosis factor-a); R&D Systems, Minneapolis,
MN, USA).49–51 CRP and the cytokines were measured in the
General Clinical Research Center Laboratories of Harbor-UCLA
Medical Center. Plasma total homocysteine concentrations were
determined by high-performance liquid chromatography at Harbor-
UCLA Clinical Laboratories.
Measurement of HII
In addition to its role in reverse cholesterol transport (that is, from
peripheral tissues to the liver for excretion in the bile), normal HDL
has anti-oxidant and anti-inflammatory properties. In the presence
of excessive metabolic and oxidative stress, HDL loses its protective
capacity and can become proinflammatory. To determine HDL
inflammatory properties, sera for assay were sucrose cryopreserved
without EDTA, and HDL-containing supernatants were prepared by
removal of the apolipoprotein B-containing proteins by a modifica-
tion of previously described methods18,52 as recently performed by
McMahon et al.36 The HDL containing supernatants were prepared
using HDL Magnetic Bead Reagent (catalog no. 5030, Polymedcoa).
Two hundred microliters of sera were incubated with 40 ml of the
Magnetic Bead Reagent at room temperature for 5 min. The mixture
was placed on the magnetic particle concentrator for 3 min and the
HDL-containing supernatant was removed. The fluorescence of LDL
was determined in the absence or presence of the test HDL by a
minor modification of the procedures described previously.18,52
Briefly, dichlorofluorescein diacetate (DCFH-DA) was dissolved in
fresh methanol and incubated at room temperature and protected
from light for 30 min, resulting in the release of DCFH. Ten
microliters containing 0.5 mg of normal human LDL-cholesterol was
added to wells with or without the HDL-containing supernatants
(90ml containing 0.45 mg of HDL-cholesterol) in round-bottom,
black polypropylene microtiter plates and mixed. The plates were
then incubated at 371C on a rotator for 1 h. DCFH solution (10 ml
containing 2 mg DCFH) was then added to each well including wells
without lipoproteins, mixed, and incubated with rotation at 371C
for 2 h while being protected from light. Fluorescence was
determined with a plate reader. Fluorescence intensity was
determined with a Farrand (Valhalla, NY, USA) system 3 scanning
spectrofluorometer set at an excitation wavelength of 485 nm and an
emission wavelength of 530 nm.52 A sensitivity level of 0.1 and slit
widths of 2.5 and 10 nm were used for excitation and emission,
respectively.52 The fluorescence values from wells without lipopro-
teins were subtracted from the values of the wells with lipoproteins.
Values in the absence of HDL were normalized to 1.0. The values
obtained in the presence of the test HDL were divided by the value
obtained in the absence of HDL to yield the HII. Values 41.0 after
the addition of the test HDL indicated proinflammatory HDL;
values o1.0 indicated anti-inflammatory HDL.18,52 In some cases,
the values for fluorescence in wells containing LDL together with the
test HDL were less than the fluorescence values of wells containing
only DCFH. In these instances, the HII values were not only o1.0,
they were negative values.
Statistical methods
Conventional t-tests were used to detect significant differences
among HII levels, that is, HIIo1 versus HIIX1. w2 and rank tests
were used for categorical variables. Pearson’s correlation coefficient
(r) was used for analyses of associations. Multivariate regression
analyses and analysis of covariance were performed to obtain
adjusted P-values controlled for case-mix and comorbidity covari-
ates. Logistic regression models were fitted to construct odds ratio of
HII41 within the body fat percentage categories controlling for
confounding covariates. To calculate the relative risks of death, we
obtained hazard ratios using Cox proportional hazard models after
controlling for the above-mentioned covariates. Plots of log (log
(survival rate)) against log (survival time) were performed to
establish the validity of the proportionality assumption. Kaplan–-
Meier analyses were utilized to assess the differences in surviving
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proportions between the two HII categories. Case-mix and
comorbidity covariates included gender, age, race and ethnicity
(Hispanics, Blacks, Asians, and others), diabetes mellitus, Charlson
comorbidity scale, and dialysis vintage (number of months on MHD
treatment); and laboratory surrogates of MICS in fully adjusted Cox
models included serum CRP, IL-6, and albumin concentrations.
Fiducial limits are given as mean7s.d. or median and interquartile
range. Risk ratios include 95% confidence interval levels. A Po0.05
or a 95% confidence interval that did not span 1.0 was considered to
be statistically significant. A P-value between 0.05 and 0.20 is also
listed with two decimals to identify potential type II errors.
Descriptive and multivariate statistics were carried out with the
statistical software ‘Stata version 9.0’ (Stata Corporation, College
Station, TX, USA).
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